Keywords: antigenics, starts, cml, study, firm, started, 120-patient

Antigenics starts CML study

Article | 14 April 2003

Print This

US firm Antigenics has started a 120-patient, Phase II trial of itsAG-858 cancer vaccine, in combination with Novartis' Gleevec/ Glivec ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in